Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI, China, Aug. 29, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”), alongside the Office of the Assistant Secretary for Preparedness and Response, has resumed the shipment and distribution of etesevimab and bamlanivimab administered together (the “Therapy”), according to the company's global partner Eli Lilly and Company (NYSE: LLY). Direct ordering will be available to authorized states in the U.S. effective immediately.

Distribution of Etesevimab/JS016 in the US Reopened

Eli Lilly And Co (NYSE: LLY) and Boehringer Ingelheim have rolled out full results of EMPEROR-Preserved phase 3 trial of Jardiance (empagliflozin) for heart failure with preserved ejection fraction (HFpEF).  The data was delivered at the annual meeting of the European Society of Cardiology (ESC).

Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in adults with HFpEF

Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 27, 2021 /PRNewswire/ -- Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance® (empagliflozin) showed an impressive 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF) compared with placebo.

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Eli Lilly updated investors on its ongoing phase 3 trials to treat patients who have moderate to severe eczema with a new drug.

This Potential Indication Could Mean Profit for Eli Lilly Investors

INDIANAPOLIS, Aug. 25, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) announced today that Carolyn R. Bertozzi, Ph.D.

Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.

Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders

Novo Nordisk

Pfizer

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)

Sanofi

House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supposed concern over the past two years with the price of insulin, the price still remains "unacceptably high." Committee chair Frank Pallone (D-NJ) and subcommittee chair Diana DeGette (D-CO) note in all three letters that the price of insulin in the U.S. is more than 10 times that of 33 other countries.

House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices

Lilly's (LLY) Jardiance gets FDA approval for heart failure with reduced ejection fraction (HFrEF), based on data from the phase III EMPEROR-Reduced study

Lilly's (LLY) Jardiance Gets FDA Approval for Heart Failure

The FDA approves Eli Lilly And Co (NYSE: LLY) - Boehringer Ingelheim's Jardiance (empagliflozin) 10 mg for heart failure. The approval comes to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF).

FDA Approves Eli Lilly's Jardiance For Heart Failure

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 18, 2021 /PRNewswire/ -- Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On

Eli Lilly's (LLY) two phase III studies on lebrikizumab meet the primary and all key secondary endpoints.

Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal

Eli Lilly & Co. LLY, +2.17% announced Tuesday that it will split its Lilly Bio-Medicines division into two business units: Lilly Neuroscience and Lilly Immunology, effective September 5. Lilly Neuroscience will be led by Anne White, currently president of Lilly Oncology, now responsible for launched products and the unit's phase 3 portfolio in pain and neurodegeneration, including the potential launch of an Alzheimer's drug, donanemab.

Eli Lilly creates neuroscience and immunology business units

INDIANAPOLIS, Aug. 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership changes and the creation of neuroscience and immunology business units. These changes will increase Lilly's focus on introducing breakthrough new medicines to millions of people with unmet needs.

Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units

Insulet

The FDA has approved the use of Eli Lilly And Co's (NYSE:LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ:PODD) insulin management systems. Lyumjev, approved by the FDA in June 2020, is a formulation of insulin lispro to speed insulin absorption into the bloodstream.

FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps

Eli Lilly And Co's (NYSE: LLY) lebrikizumab ADvocate 1 and ADvocate 2 Phase 3 clinical trials met primary and all key secondary endpoints at Week 16.  Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis (AD) in the two Phase 3 trials.

Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials

INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY) rapid-acting insulin, Lyumjev® (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous insulin infusion (CSII) with an insulin pump. Lyumjev, a novel formulation of insulin lispro developed to speed the absorption of insulin into the bloodstream and reduce A1C levels, was approved by the FDA in June 2020.

FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps

INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company's (NYSE: LLY) ADvocate 1 and ADvocate 2 Phase 3 clinical trials. In the top-line results from these two studies of lebrikizumab as a monotherapy in AD, primary and all key secondary endpoints, including skin clearance and itch improvement, were met at Week 16.

Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

Carvana

Alphabet

Jefferies Financial Group Inc

Kellogg

When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock.

5 Stocks Insiders Are Selling

Bayer AG

These stocks offer solid growth opportunities.

3 Pharma Stocks to Buy in August

Option trading activity after earnings indicates that traders are still confident in Eli Lilly's (LLY) share price going forward.

Eli Lilly (LLY) Option Traders Confident After Earnings

Among the five largest biotechnology companies in the world, as measured by market capitalization, Eli Lilly and Co. ( LLY , Financial) has given shareholders the biggest bang for their buck. The stock of the Indianapolis-based pharmaceutical giant has climbed 78% in the past year and more than 260% since August 2016.

Shares of Eli Lilly Have Soared in Past 5 Years

Archer-Daniels-Midland Company

Aflac

Amgen

American States Water

Chevron

Emerson Electric

Honeywell

Microsoft

Starbucks

Charles Schwab

Target

Visa

Walgreens

Walmart

Exxon Mobil

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

News for Eli Lilly Stock (LLY)